OOIR: Observatory of International Research

Papers

(The H4-Index of Alzheimers & Dementia is 71. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
The Design of SPRINT MIND and SPRINT MIND 2020	2932
Survey on knowledge of Uruguayan neurologist about the FINGER intervention	2453
Approach for developing interpretative cut‐points during implementation of a plasma p‐tau217 assay in the clinical laboratory	2249
Exploring Alzheimer’s disease progression through the lens of genetics and sleep disturbances	514
The power of cognitive rehabilitation in Alzheimer’s disease ‐A Systematic review and meta analysis	353
Examining the impact of hormone therapy and Alzheimer’s disease risk factors on depressive symptoms in the Harvard Aging Brain Study	260
Relationship between perivascular spaces and white matter hyperintensities in Alzheimer’s disease	241
Neural flexibility as a promising biomarker for Alzheimer’s Disease	236
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	213
The Types and Consistency of Participant‐Specified Proxies During SPRINT	213
Putative Cellular Identity of Dystrophic Neurites in FTLD‐TDP Type C	205
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	200
Investigating the Association Between P2Y12 Receptor, SV2A, and Tau Expression in Postmortem AD and Control Brains Using In Vitro Autoradiography	192
Neuroprotective Potential of Limonene in LPS induced Parkinson’s Disease in Rats	172
Glial and synaptic biomarkers as early indicators of mild cognitive decline	158
Use of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease	154
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	151
Longitudinal neuropsychological evaluation allows diagnosis of MCI with less severe memory change	150
Physical Activity, Social Support, and the Health of Dementia Caregivers: A Scoping Review	134
Frontotemporal Dementia & the Criminal Legal System: Care Partner Stories	129
Childhood trauma and cognition status in an elderly sample with a mental disorder	128
SENSE‐Cog Residential Care: A Pilot Cluster Randomized Trial on Hearing and Vision Support for Residents with Dementia in Long‐term Care	127
Who Uses Memory Strategies? Exploring the Influence of Cognitive Reserve on Use of Memory Strategies by Older Adults Referred for Neuropsychological Assessment	126
Reducing Gerontophobia and Improving Cognition: A Study on the Efficacy of Mindfulness‐Based Cognitive Therapy in Older Adults in India	125
Ciclosonide reduces lipid droplet burden in APOE4 astrocytes	122

“CLOVER” Model of Service and Training Development for the Well‐being of People with Dementia in Residential Care Homes of Hong Kong	120
The Dementia Literacy Assessment (DeLA): A Novel Measure of Alzheimer's Disease and Related Disorders Health Literacy in Diverse Populations	117
An interrupted time‐series design experiment of research registry recruitment interventions	112
Pterostilbene Ameliorates Hyperhomocysteinemia‐Induced Cognitive Impairment: Involvement of Mitochondrial Dysfunction, Synaptic Plasticity, and Adult Neurogenesis	111
“ I know you didn’t want to stay ”: Emergency Department Conversations about Disposition for People Living with Dementia	108
Herbal Therapeutics in Alzheimer's Disease: Investigating Behavioral and Biochemical Changes in Animal Model	108
Dementia registry in Guinea: clinical and etiological aspects at the Neurological Department of the Conakry teaching Hospital	107
Simultaneous reduction of amyloid beta and phosphorylated tau for Alzheimer’s Disease with Chemically Optimized Stringed Modifiable Oligonucleotides (COSMOs)	106
The Utility of the WMS‐IV LM Subtest as an Inclusionary Measure in Early AD Trials	105
Impact of icosapent ethyl on CSF NULISA vascular, metabolic, and AD biomarkers in cognitively unimpaired Veterans at risk for dementia	101
Anti‐NMDA Receptor Encephalitis in a Young Adult with Neuropsychiatric and Cognitive Symptoms‐ A Case Study	100
Natural Language Processing differentiates between Italian individuals with Nonfluent/Agrammatic from Logopenic variants of PPA	99
False Negative Twenty‐Nine Montreal Cognitive Assessment Score in Moderately ADL‐Impaired UDS Patients: A Case Series Study of 23 Patients	99
The glymphatic system's role in linking cardiometabolic health to cerebral small vessel disease and frailty in Chilean healthy older adults	99
Neuropsychiatric symptom subtypes associated with Alzheimer's disease and related dementia neuropathologic changes in the National Alzheimer's Coordinating Center neuropathology cohort	96
Cross‐ validation of Free‐Cog with routinely used cognitive and functional tools in Canadian Memory Clinics	96
Neuropsychiatric Symptoms in Comorbid Alzheimer's Disease Neuropathologic Change and Frontotemporal Lobar Degeneration	93
Implementation of AD BBMs: Approach in Memory Clinics in the Netherlands	91
Genetic Intersections of ADHD and Alzheimer's Disease: A Systematic Review	90
Association of MBI‐C scores with clinical outomes in patients with MCI during a 3‐year follow‐up	90
Effect of Orexin receptor antagonists for patients with Lewy bodies: Lemborexant do not make worse cognitive function and REM sleep Behavior Disorder in DLB	89
Achieving Dissemination and Implementation Success in Dementia Care: A Consideration of Methodological Strategies	89
The Impact of Testing Environments on Remote Cognitive Assessments in Alzheimer's Disease	88
Trip‐Based Measures of Naturalistic Driving: Exploring connections to older adult drivers with respect to amyloid‐positive and amyloid‐negative	87
Predicting brain health in older adults through automated language measures	86
Sensory Healthcare for People with Dementia in Diverse Care Settings	85
Rare Dementia Support Canada: Localizing and mobilizing knowledge to build inclusive supports for families affected by atypical dementias	85
Women are less likely to be eligible for AD trials than men.	85
Distinct trajectories of subjective cognitive decline before diagnosis of neurocognitive disorders: Longitudinal modelling over 18 years	84
Nutritional status and eating disturbances among patients with neurocognitive disorder	83
EMA perspective on Diagnosis of Alzheimer's	83
Cerebellar degeneration and its integrative role in brain networks for social cognition in early‐stage bvFTD	83
The Moderating Effect of Perceived Susceptibility and Decision Conflict on the Relationship Between Comorbidities and Quality of Life Among Caregivers of People with Dementia	82
Pulse pressure is associated with Alzheimer's disease pathology and cognitive decline	81
Evaluating the effect of ethnicity and amyloid on gait speed in the Healthy Aging Brain Study‐Health Disparities Study	81
Domestic Environment of Multisensory Stimulation based on Snoezelen principles pilot study	80
Dementia Dastan: Understanding the Experiences of South Asian Canadians Living with Dementia and their Care Partners	80
Evaluating the impact of delayed auditory feedback in primary progressive apraxia of speech: acoustic, perceptual, and patient reported outcomes	78
What is the prevalence of impaired cognitive domains in surgical patients? A systematic review and meta‐analysis	78
Divergent Functional Capacity in Alzheimer's Disease and Frontotemporal Dementia: Insights from the Peruvian Adaptation of the Amsterdam Instrumental Activities of Daily Living Questionnaire	77
The Psychological Impact of Receiving a Biomarker Informed ADRD Diagnosis in a Real‐World Sample: the PARADE Study	76
Exploring Memory Trajectories in Aging: A Longitudinal Study of Superagers and Memory Maintenance	74
Exploring Emotional Well‐Being in Exceptional Aging: Data from the SuperAging Research Initiative	74
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	73
Speed of cognitive decline in biomarker stratified SCD subgroups	73
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	72
Automating the verbal paired associates test to assess memory remotely and at scale	71
Discerning neurodegenerative and aging genetic influences on hippocampal subfields trajectories in the Alzheimer’s disease continuum	71